Kras (p.G12C) Point Mutation in LL/2 (LLC1) Cell Line
The Kras (p.G12C) Point Mutation in LLC Cell Line is based on the newly developed Bingo™ platform, which utilizes an optimized and upgraded version of the Prime Editing (PE) gene point mutation system-currently the most efficient and safest technology available. This platform enables precise and efficient gene point mutation, resulting in a highly active and stable cell line.
Product Details
| Cat.No. | EDC03013 | Product Name | Kras (p.G12C) Point Mutation in LL/2 (LLC1) Cell Line |
|---|---|---|---|
| Cell Line | LL/2 (LLC1) | Gene ID | |
| Cellosaurus ID | CVCL_4358 | Mutation Site | p.G12C |
| Cell Line Synonyms | LL/2 (LLc1), LL/2(LLc1), LL/2, LL2, LLC1, LLC, Lewis lung carcinoma line 1, Lewis lung carcinoma, Lewis Lung Cancer, Lewis-Lung, Lewis Lung | Associated Diseases | Lung cancer |
| Passage Ratio | 1:3~1:4 | Complete Culture Medium | DMEM+10%FBS |
| Freezing Medium | 95% complete culture medium+5% DMSO |
STR Profile
| Loci | STR Info (Sample Cell) Sample Cell Line: LL/2 (LLC1) | STR Info (Cell bank) Cell Line: LL/2 (LLC1) | ||||||
| Allele1 | Allele2 | Allele3 | Allele4 | Allele1 | Allele2 | Allele3 | Allele4 | |
| 1-1 | 15 | 16 | 17 | 18 | 15 | 16 | 17 | 18 |
| 1-2 | 18 | 19 | 18 | 19 | ||||
| 2-1 | 16 | 16 | ||||||
| 3-2 | 13 | 14 | 13 | 14 | ||||
| 4-2 | 21.3 | 23.3 | 21.3 | 23.3 | ||||
| 5-5 | 16 | 17 | 16 | 17 | ||||
| 6-4 | 18 | 18 | ||||||
| 6-7 | 15 | 15 | ||||||
| 7-1 | 27.2 | 27.2 | ||||||
| 8-1 | 16 | 17 | 16 | 17 | ||||
| 11-2 | 13.3 | 14.3 | 15.3 | 13.2 | 14.2 | 15.2 | ||
| 12-1 | 17 | 17 | ||||||
| 13-1 | 18.1 | 18.1 | ||||||
| 15-3 | 24.3 | 25.3 | 26.3 | 24.3 | 25.3 | |||
| 17-2 | 14 | 15 | 14 | 15 | ||||
| 18-3 | 15 | 16 | 15 | 16 | ||||
| 19-2 | 13 | 13 | ||||||
| X-1 | 25 | 26 | 25 | 26 | ||||
Conclusion: The STR identification of this cell is correct.